- Home
- STTK vs STSS Comparison
STTK vs STSS Comparison
Compare STTK & STSS Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- STTK
- STSS
- Stock Information
- Founded
- STTK 2016
- STSS 2017
- Country
- STTK United States
- STSS United States
- Employees
- STTK N/A
- STSS N/A
- Industry
- STTK Biotechnology: Pharmaceutical Preparations
- STSS Medical/Dental Instruments
- Sector
- STTK Health Care
- STSS Health Care
- Exchange
- STTK Nasdaq
- STSS Nasdaq
- Market Cap
- STTK 112.6M
- STSS 124.5M
- IPO Year
- STTK 2020
- STSS 2022
- Fundamental
- Price
- STTK $1.96
- STSS $3.66
- Analyst Decision
- STTK Hold
- STSS
- Analyst Count
- STTK 5
- STSS 0
- Target Price
- STTK $3.00
- STSS N/A
- AVG Volume (30 Days)
- STTK 162.8K
- STSS 168.8K
- Earning Date
- STTK 11-06-2025
- STSS 11-13-2025
- Dividend Yield
- STTK N/A
- STSS N/A
- EPS Growth
- STTK N/A
- STSS N/A
- EPS
- STTK N/A
- STSS N/A
- Revenue
- STTK $1,000,000.00
- STSS $222,722.00
- Revenue This Year
- STTK N/A
- STSS N/A
- Revenue Next Year
- STTK N/A
- STSS N/A
- P/E Ratio
- STTK N/A
- STSS N/A
- Revenue Growth
- STTK N/A
- STSS N/A
- 52 Week Low
- STTK $0.69
- STSS $3.36
- 52 Week High
- STTK $2.71
- STSS $1,248.27
- Technical
- Relative Strength Index (RSI)
- STTK 49.33
- STSS 31.73
- Support Level
- STTK $1.86
- STSS $3.63
- Resistance Level
- STTK $2.06
- STSS $4.04
- Average True Range (ATR)
- STTK 0.14
- STSS 0.34
- MACD
- STTK -0.00
- STSS -0.00
- Stochastic Oscillator
- STTK 43.64
- STSS 1.61
About STTK Shattuck Labs Inc.
Shattuck Labs Inc is a biotechnology company specializing in the development of potential treatments for inflammatory and immune-mediated diseases. It is developing a potentially first-in-class antibody for the treatment of inflammatory bowel disease (IBD) and other inflammatory and immune-mediated diseases. The company's expertise in protein engineering and the development of novel tumor necrosis factor (TNF) receptor therapeutics comes together in its main program, SL-325, which has the potential to be a first-in-class death receptor 3 (DR3) antagonist antibody. In addition, the company is developing SL-425, a half-life extended version of SL-325, and multiple other preclinical DR3-based bispecific antibodies, for the treatment of patients with IBD.
About STSS Sharps Technology Inc.
Sharps Technology Inc is a medical device company. It offers syringes and other safety products. Sharps provensa, Securgard, and Sologard are ultra-low waste smart safety syringes designed to eliminate potentially infectious and accidental needlestick injuries.